These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 26663620)
41. Nifedipine maintenance tocolysis and perinatal outcome: an individual participant data meta-analysis. van Vliet E; Dijkema GH; Schuit E; Heida KY; Roos C; van der Post J; Parry EC; McCowan L; Lyell DJ; El-Sayed YY; Carr DB; Clark AL; Mahdy ZA; Uma M; Sayin NC; Varol GF; Mol BW; Oudijk MA BJOG; 2016 Oct; 123(11):1753-60. PubMed ID: 27550838 [TBL] [Abstract][Full Text] [Related]
42. Relation of body mass index to frequency of recurrent preterm birth in women treated with 17-alpha hydroxyprogesterone caproate. Co AL; Walker HC; Hade EM; Iams JD Am J Obstet Gynecol; 2015 Aug; 213(2):233.e1-5. PubMed ID: 25912300 [TBL] [Abstract][Full Text] [Related]
43. The use of progestational agents for preterm birth: lessons from a mouse model. Elovitz MA; Mrinalini C Am J Obstet Gynecol; 2006 Oct; 195(4):1004-10. PubMed ID: 17000233 [TBL] [Abstract][Full Text] [Related]
44. Meta-analysis of randomized controlled trials comparing 17α-hydroxyprogesterone caproate and vaginal progesterone for the prevention of recurrent spontaneous preterm delivery. Oler E; Eke AC; Hesson A Int J Gynaecol Obstet; 2017 Jul; 138(1):12-16. PubMed ID: 28369874 [TBL] [Abstract][Full Text] [Related]
46. Progestogens for the prevention of preterm birth and risk of developing gestational diabetes mellitus: a meta-analysis. Pergialiotis V; Bellos I; Hatziagelaki E; Antsaklis A; Loutradis D; Daskalakis G Am J Obstet Gynecol; 2019 Nov; 221(5):429-436.e5. PubMed ID: 31132340 [TBL] [Abstract][Full Text] [Related]
47. What agent should be used to prevent recurrent preterm birth: 17-P or natural progesterone? Hall NR Obstet Gynecol Clin North Am; 2011 Jun; 38(2):235-46, ix-x. PubMed ID: 21575799 [TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetics of 17 alpha hydroxyprogesterone caproate in singleton pregnancy and its influence of maternal body size measures. Della Torre M; Enakpene C; Ravangard S; DiGiovanni L; Deyo K; Whelan A; Sutherland M; Fischer J Am J Obstet Gynecol MFM; 2019 Nov; 1(4):100051. PubMed ID: 33345841 [TBL] [Abstract][Full Text] [Related]
51. Smoking, 17 Alpha-Hydroxyprogesterone Caproate, and Preterm Birth. Heyborne KD; Allshouse AA Am J Perinatol; 2016 Oct; 33(12):1191-7. PubMed ID: 27464018 [TBL] [Abstract][Full Text] [Related]
52. Perinatal outcome in women treated with progesterone for the prevention of preterm birth: a meta-analysis. Sotiriadis A; Papatheodorou S; Makrydimas G Ultrasound Obstet Gynecol; 2012 Sep; 40(3):257-66. PubMed ID: 22611023 [TBL] [Abstract][Full Text] [Related]
53. Optimal routes of administration, vehicles and timing of progesterone treatment for inhibition of delivery during pregnancy. Fang D; Moreno M; Garfield RE; Kuon R; Xia H Eur J Obstet Gynecol Reprod Biol; 2017 Sep; 216():164-168. PubMed ID: 28777967 [TBL] [Abstract][Full Text] [Related]
54. 17-α hydroxyprogesterone caproate for the prevention of preterm birth. Gupta S; Roman AS Womens Health (Lond); 2012 Jan; 8(1):21-30. PubMed ID: 22171770 [TBL] [Abstract][Full Text] [Related]
55. Effect of 17-alpha hydroxyprogesterone caproate on cervical length in twin pregnancies. Lim AC; Schuit E; Papatsonis D; van Eyck J; Porath MM; van Oirschot CM; Hummel P; Hasaart TH; Kleiverda G; de Graaf IM; van Ginkel AA; Mol BW; Bruinse HW Ultrasound Obstet Gynecol; 2012 Oct; 40(4):426-30. PubMed ID: 23008102 [TBL] [Abstract][Full Text] [Related]
56. Impact of prior gestational age at preterm delivery on effectiveness of 17-alpha-hydroxyprogesterone caproate in practice. González-Quintero VH; de la Torre L; Rhea DJ; Tudela CM; Vazquez-Vera E; Desch C; Istwan NB Am J Obstet Gynecol; 2010 Sep; 203(3):257.e1-5. PubMed ID: 20678745 [TBL] [Abstract][Full Text] [Related]
58. Pessary placement in the prevention of preterm birth in multiple pregnancies: a propensity score analysis. Monfrance MJ; Schuit E; Groenwold RH; Oudijk MA; de Graaf IM; Bax CJ; Bekedam DJ; Mol BW; Langenveld J Eur J Obstet Gynecol Reprod Biol; 2016 Feb; 197():72-7. PubMed ID: 26706925 [TBL] [Abstract][Full Text] [Related]
59. A randomized controlled trial of intramuscular versus vaginal progesterone for the prevention of recurrent preterm birth. Elimian A; Smith K; Williams M; Knudtson E; Goodman JR; Escobedo MB Int J Gynaecol Obstet; 2016 Aug; 134(2):169-72. PubMed ID: 27168167 [TBL] [Abstract][Full Text] [Related]
60. Medical cost savings associated with 17 alpha-hydroxyprogesterone caproate. Bailit JL; Votruba ME Am J Obstet Gynecol; 2007 Mar; 196(3):219.e1-7. PubMed ID: 17346527 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]